Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | ASPH | Q12797 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300999 | 1.00 | P4HTM (0.53) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL5123658 | 0.87 | AURKA (0.51) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL10329128 | 0.86 | P4HTM (0.50) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL17162305 | 0.86 | P4HTM (0.54) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL17520868 | 0.85 | P4HTM (0.49) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 | |
| SCHEMBL30489408 | 0.84 | KMT2A (0.57) | KDM4EL3MBTL1MAPK1MEN1KMT2A | |
| SCHEMBL795658 | 0.84 | MEN1 (0.49) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| Potassium Ion SCHEMBL796078 | 0.83 | KMT2A (0.45) | P4HTML3MBTL1MEN1KMT2ANPC1 | |
| SCHEMBL796465 | 0.83 | MAPK1 (0.57) | KDM4EL3MBTL1MAPK1MEN1KMT2A | |
| SCHEMBL17162444 | 0.82 | P4HTM (0.50) | P4HTMKDM4EL3MBTL1MAPK1P4HA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410210-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250154194-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-12264177-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-12252509-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20240343756-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| US-20240336648-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| US-20240309042-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2024-09-19 | — | — | US | disclosed |
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-11999765-B2 | Neuroactive steroids and their methods of use | SAGE THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230322849-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| CN-116134018-A | 2-oxoimidazolidine-4-carboxamide as NAV1.8 inhibitor | 默沙东有限责任公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4168393-A1 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| CN-115947681-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20230046825-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | SAGE THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-109641854-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-109641844-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-114401952-A | Substituted cycloalkyl compounds as modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114206856-A | Anti-malarial hexahydropyrimidine analogues | UCB生物制药有限责任公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3962899-A1 | SUBSTITUTED CYCLOLAKYLS AS MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322849-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | P4HTM 3379/4885KDM4E 2463/4885L3MBTL1 3179/4885 |
| US-20240336648-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | P4HTM 3331/4885KDM4E 2473/4885L3MBTL1 3237/4885 |
| US-20250154194-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | P4HTM 3331/4885KDM4E 2473/4885L3MBTL1 3237/4885 |
| US-12410210-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | P4HTM 3331/4885KDM4E 2473/4885L3MBTL1 3237/4885 |
| US-20240309042-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | P4HTM 3294/4885KDM4E 2421/4885L3MBTL1 3277/4885 |
| US-12252509-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | P4HTM 3331/4885KDM4E 2473/4885L3MBTL1 3237/4885 |
| US-20240343756-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | P4HTM 3379/4885KDM4E 2463/4885L3MBTL1 3179/4885 |
| US-12264177-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | P4HTM 3331/4885KDM4E 2473/4885L3MBTL1 3237/4885 |
| US-11999765-B2 | Neuroactive steroids and their methods of use | NR3C2, MC2R, NR3C1 | P4HTM 3331/4885KDM4E 2473/4885L3MBTL1 3237/4885 |
| US-20230046825-A1 | NEUROACTIVE STEROIDS AND THEIR METHODS OF USE | NR3C2, MC2R, NR3C1 | P4HTM 3379/4885KDM4E 2463/4885L3MBTL1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.